A Predictive Model of Plasma Lamotrigine Levels

Abstract

Introduction: Lamotrigine is one of several mood stabilizers and its effects for the treatment and prevention of depressive episodes, particularly in bipolar disorder, are generally accepted. Although the findings about a therapeutic window of lamotrigine are yet to be determined, it seems important to obtain information on individual pharmacokinetic peculiarities. This study was conducted to formulate the predictive model of plasma lamotrigine levels.

Methods: Using the data of 47 patients whose lamotrigine levels, liver function, and renal function were measured, predictive models of lamotrigine levels were formulated by stepwise multiple regression analyses. The predictive power of the models was compared using another dataset of 25 patients.

Results: Two models were created using stepwise multiple regression. The first model was: plasma lamotrigine level (μg/mL)=2.308+0.019×lamotrigine dose (mg/day). The second model was: plasma lamotrigine level (μg/mL)=0.08+0.024×lamotrigine dose (mg/day)+4.088×valproate combination (no=0, yes=1). The predictive power of the second model was better than that of the first model.

Discussion: The present study proposes a prompt and relatively accurate equation to predict lamotrigine levels.

Key words

lamotrigine - plasma levels - prediction - valproate

• References

• 1 Calabrese JR, Bowden CL, Sachs GS et al. Lamictal 602 Study Group. A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients with bipolar I depression. J Clin Psychiatry 1999; 60: 79-88
• 2 Calabrese JR, Huffman RF, White RL et al. Lamotrigine in the acute treatment of bipolar depression: results of five double-blind, placebo-controlled clinical trials. Bipolar Disord 2008; 10: 323-333
• 3 Geddes JR, Calabrese JR, Goodwin GM. Lamotrigine for treatment of bipolar depression: independent meta-analysis and meta-regression of individual patient data from five randomised trials. Br J Psychiatry 2009; 194: 4-9
• 4 Ketter TA, Brooks JO, Hoblyn JC et al. Effectiveness of lamotrigine in bipolar disorder in a clinical setting. J Psychiatr Res 2009; 43: 13-23
• 5 Bowden CL, Calabrese JR, Sachs G et al. Lamictal 606 Study Group. A placebo controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry 2003; 60: 392-400
• 6 Calabrese JR, Bowden CL, Sachs GS et al. Lamictal 605 Study Group. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry 2003; 64: 1013-1024
• 7 Goodwin GM, Bowden CL, Calabrese JR et al. A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium maintenance in bipolar I disorder. J Clin Psychiatry 2004; 65: 432-441
• 8 Popovic D, Reinares M, Amann B et al. Number needed to treat analysis of drugs used for maintenance treatment of bipolar disorder. Psychopharmacology 2011; 213: 657-667
• 9 Reid JG, Gitlin MJ, Altshuler LL. Lamotrigine in psychiatric disorders. J Clin Psychiatry 2013; 74: 675-684
• 10 Katayama Y, Terao T, Kamei K et al. Therapeutic window of lamotrigine for mood disorders: a naturalistic retrospective study. Pharmacopsychiatry 2014; 47: 111-114
• 11 Kagawa S, Mihara K, Nakamura A et al. Relationship between plasma concentrations of lamotrigine and its early therapeutic effect of lamotrigine augmentation therapy in treatment-resistant depressive disorder. Ther Drug Monit 2014; 36: 730-733
• 12 Unholzer S, Haen E. Retrospective analysis of therapeutic drug monitoring data for treatment of bipolar disorder with lamotrigine. Pharmacopsychiatry 2015; 48: 211-214
• 13 Johannessen SI, Landmark CJ. Antiepileptic drug interactions: principles and clinical implications. Curr Neuropharmacol 2010; 8: 254-267
• 14 Chen C, Veronese L, Yin Y. The effects of lamotrigine on the pharmacokinetics of lithium. Br J Clin Pharmacol 2000; 50: 193-195
• 15 Yuen AW, Land G, Weatherley BC et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-513
• 16 Abe Y, Yasugawa S, Miyamoto K et al. Valproate as a risk factor for lamotrigine discontinuation. J Affect Disord 2013; 150: 1197-1199
• 17 Terao T, Oga T, Nozaki S et al. A further prospective evaluation of an equation to predict daily lithium dose. J Clin Psychiatry 1995; 56: 193-195
• 18 Terao T, Okuno K, Okuno T et al. A simpler and more accurate equation to predict daily lithium dose. J Clin Psychopharmacol 1999; 19: 336-340
• 19 Hiemke C, Baumann P, Bergemann N et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235